Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of virological outcomes in kidney transplant recipients treated with maribavir for refractory cytomegalovirus infection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

End-to-side versus end-to-end uretero-ureteral anastomosis in preemptive kidney transplantation from living donors: A monocentric experience.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Renal transplantation outcomes in obese patients: a French cohort-based study.

BMC nephrology·2021
Same author

Global Transplantation COVID Report March 2020.

Transplantation·2020
Same author

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

Trials·2019
Same author

Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR).

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same journal

Alpha-Gal Syndrome: Unrecognized Risks of a Tick-Bite-Associated Allergy in Transplantation and Cellular Therapy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Comment on "Role of social determinants and outcomes of patients with alcohol-associated liver disease referred for early liver transplantation: A multicenter analysis".

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Donor Acute Kidney Injury Is Not Associated With Inferior Outcomes After Simultaneous Pancreas-Kidney Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Human Biopsy-Defined IRI-Selective Reperfusion Signature Prioritizes Reperfusion-Timed MEK Inhibition After DCD Liver Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

OPERATIONAL TOLERANCE FOLLOWING INTESTINAL TRANSPLANTATION: A CASE REPORT WITH COMPREHENSIVE IMMUNE FOLLOW-UP FROM TRANSPLANT DAY TO THREE YEARS POST-IMMUNOSUPPRESSION WITHDRAWAL.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA

R Sberro-Soussan1, J Zuber, C Suberbielle-Boissel

  • 1Université Paris Descartes, Paris, France.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|February 4, 2010
PubMed
Summary
This summary is machine-generated.

One cycle of bortezomib alone did not reduce donor-specific anti-HLA antibodies (DSA) in kidney transplant recipients with antibody-mediated rejection. Further studies are needed to assess bortezomib

Related Experiment Videos

Last Updated: Jun 16, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Donor-specific anti-HLA antibodies (DSA) persistence post-kidney transplant is linked to antibody-mediated rejection and poor graft survival.
  • Targeting plasma cells with proteasome inhibitors like bortezomib is a potential desensitization strategy.

Observation:

  • This study assessed bortezomib's efficacy as a sole desensitization therapy in four kidney transplant recipients with subacute antibody-mediated rejection and high DSA levels.
  • Bortezomib treatment involved one cycle of four doses (1.3 mg/m(2) each).

Findings:

  • Bortezomib did not significantly decrease DSA levels within 150 days post-treatment in any patient.
  • Antivirus antibody levels (HBV, VZV, HSV) remained stable, indicating no significant impact on long-lived plasma cells.

Implications:

  • One cycle of bortezomib monotherapy is insufficient to lower DSA in sensitized kidney transplant recipients within the observed timeframe.
  • Rigorous, prospective, randomized, and controlled studies are essential to properly evaluate bortezomib's role in desensitization strategies.